1. A 78-year-old woman with HFrEF (LVEF 28%) and stage 4 CKD (eGFR 19 mL/min/1.73m²) is admitted with acute decompensation. She is receiving IV furosemide 240 mg twice daily with minimal urine output. Her nephrologist explains that two distinct mechanisms are reducing furosemide delivery to NKCC2 in this patient. Which of the following best identifies both mechanisms?
A) Reduced GFR decreases the filtered load of furosemide reaching the tubular lumen, and hypoalbuminemia from CKD-related proteinuria increases the unbound free furosemide fraction, causing rapid renal clearance that prevents accumulation to effective NKCC2 concentrations
B) CKD causes upregulation of NKCC2 expression as a compensatory response to the reduced nephron mass, increasing the number of transporter sites that must be saturated before any natriuresis occurs, and accumulated uremic toxins directly bind NKCC2 and reduce its furosemide-binding affinity
C) Reduced GFR decreases tubular fluid delivery to the thick ascending limb, reducing the contact surface area available for NKCC2 blockade, and CKD-related hypokalemia reduces the driving gradient for Na-K-2Cl cotransport, making NKCC2 pharmacologically inactive regardless of furosemide concentration
D) Furosemide reaches the tubular lumen almost entirely by active secretion via OAT1 and OAT3 (organic anion transporters 1 and 3) in the proximal tubule; in advanced CKD, accumulated uremic organic acids (including hippurate and indoxyl sulfate) compete with furosemide for OAT1/OAT3 transport, reducing luminal furosemide delivery; additionally, furosemide is greater than 95% protein-bound, and reduced renal blood flow in low-output CKD impairs peritubular capillary flow past the OAT secretion sites, further reducing the rate of tubular secretion
E) CKD reduces hepatic albumin synthesis, causing hypoalbuminemia that traps furosemide in tubular fluid as protein-albumin complexes before it can bind NKCC2, and uremic retention of organic acids competitively displaces furosemide from NKCC2 binding sites in the thick ascending limb, requiring doses above 400 mg IV to overcome both mechanisms simultaneously
ANSWER: D
Rationale:
In advanced CKD, two pharmacokinetic mechanisms converge to reduce furosemide delivery to its site of action. First, furosemide reaches the tubular lumen almost entirely via active secretion by the organic anion transporters OAT1 and OAT3 in the proximal tubule — not by glomerular filtration. Uremic organic acids that accumulate in CKD (hippurate, indoxyl sulfate, p-cresyl sulfate, and other retained solutes) compete with furosemide for binding and transport by OAT1/OAT3, directly reducing the rate of furosemide secretion into the proximal tubular lumen. Second, furosemide is greater than 95% protein-bound in plasma. Peritubular delivery of the albumin-furosemide complex to OAT1/OAT3 depends on adequate renal blood flow; in CKD combined with low cardiac output (as in HFrEF), reduced peritubular capillary flow impairs the rate at which the albumin-furosemide complex is presented to OAT transporters per unit time, compounding the competitive inhibition problem. The result is substantially reduced luminal furosemide concentrations at NKCC2, requiring dramatically higher administered doses to achieve adequate natriuresis.
Option A: Option A is incorrect: furosemide reaches the tubular lumen by secretion rather than filtration, so reduced GFR does not directly reduce luminal drug delivery via a filtered-load mechanism; and while hypoalbuminemia does alter free fraction kinetics, rapid renal clearance of free furosemide is not the established primary mechanism of CKD-related resistance.
Option B: Option B is incorrect: NKCC2 upregulation is not an established CKD compensation for reduced nephron mass in the clinically relevant sense described, and uremic toxins do not directly bind NKCC2 to reduce its furosemide affinity — their competitive inhibition is at OAT1/OAT3, not at NKCC2 itself.
Option C: Option C is incorrect: CKD-related hypokalemia does not render NKCC2 pharmacologically inactive; Na-K-2Cl cotransport depends on sodium and chloride gradients maintained by the Na-K-ATPase, and the driving gradient is not abolished by hypokalemia in the clinical ranges seen in CKD.
Option E: Option E is incorrect: furosemide is not trapped by albumin-furosemide complexes in the tubular fluid before binding NKCC2; once secreted into the lumen, furosemide dissociates from albumin (albumin does not pass the glomerular filter in significant amounts in the context of drug delivery) and acts on the luminal face of NKCC2 as free drug; uremic organic acids compete at OAT transporters, not at NKCC2.
2. A 70-year-old man with HFrEF is admitted for acute decompensation and started on IV furosemide at 2.5 times his oral daily dose per DOSE trial-informed strategy. At 48 hours his creatinine has risen from 1.3 to 1.7 mg/dL. His JVP (jugular venous pressure) remains elevated, he has lost 3 kg, blood pressure is 108/66 mmHg, and urine output has been 150–200 mL/hour. Which of the following best applies DOSE trial findings to the management of this creatinine rise?
A) The DOSE trial demonstrated that high-dose IV furosemide produces greater decongestion and symptomatic improvement at 72 hours compared to low-dose, with a modest non-significant creatinine increase that did not translate into worse 60-day outcomes; this patient's creatinine rise occurred during effective decongestion (weight loss, elevated JVP, adequate urine output, stable hemodynamics), consistent with acceptable worsening renal function — continued diuresis at the current dose with monitoring is appropriate
B) The DOSE trial established that any creatinine rise above 0.3 mg/dL during high-dose IV diuresis requires immediate dose reduction to the low-dose equivalent (1× the oral daily dose) to prevent progression to dialysis-requiring acute kidney injury; because this patient's creatinine has risen 0.4 mg/dL, furosemide must be reduced and renal function reassessed before continuing
C) The DOSE trial demonstrated equivalence between high- and low-dose strategies for decongestion, with the high-dose arm showing significantly worse renal outcomes at 60 days; this creatinine rise confirms that the DOSE trial's cautionary finding applies to this patient, and switching to continuous infusion at the low-dose equivalent is the evidence-based response
D) The creatinine rise indicates that this patient has developed cardiorenal syndrome type 3 (acute kidney injury causing acute cardiac decompensation); per post-DOSE trial guidance, the first response is IV normal saline 500 mL to restore renal perfusion, followed by reassessment of JVP and urine output before resuming any diuretic
E) The DOSE trial found that high-dose diuresis was associated with a significant increase in 60-day all-cause mortality compared to low-dose diuresis despite superior short-term decongestion; this mortality signal means that any creatinine rise during high-dose therapy should prompt immediate transition to ultrafiltration, which achieves equivalent decongestion without the nephrotoxic tubular effects of high-dose loop diuretics
ANSWER: A
Rationale:
The DOSE trial's key finding regarding renal outcomes is directly applicable here: high-dose IV furosemide (2.5× the oral daily dose) produced a modest, non-significant increase in creatinine compared to low-dose strategy, and this creatinine increase did not translate into worse 60-day clinical outcomes — no significant difference in mortality, rehospitalization, or long-term renal function was observed. The clinical lesson is that a modest creatinine rise during effective high-dose diuresis is an expected and generally acceptable pharmacological consequence, not an automatic indication to reduce the dose. This patient's clinical picture is consistent with acceptable worsening renal function: he remains volume overloaded (elevated JVP), is losing weight (3 kg in 48 hours), is producing adequate urine output, and is hemodynamically stable (blood pressure 108/66 mmHg without hypoperfusion signs). Stopping or reducing furosemide at this point risks incomplete decongestion — and persistent congestion at discharge is a stronger predictor of 30-day readmission than a transient in-hospital creatinine rise during effective diuresis. Continued diuresis with close monitoring is the DOSE trial-supported approach.
Option B: Option B is incorrect: the DOSE trial did not establish a 0.3 mg/dL creatinine threshold mandating dose reduction; the trial's finding was specifically that the modest creatinine rise in the high-dose arm did not worsen outcomes, which argues against reflexive dose reduction.
Option C: Option C is incorrect: this inverts the DOSE trial findings — the trial showed high-dose was superior for decongestion, not equivalent; and continuous infusion was not superior to bolus dosing.
Option D: Option D is incorrect: cardiorenal syndrome type 3 is AKI causing acute cardiac dysfunction — not the situation described here, which is cardiac-driven AKI during effective diuresis; and IV normal saline would worsen the patient's persistent congestion.
Option E: Option E is incorrect: the DOSE trial did not show a significant increase in 60-day all-cause mortality with high-dose diuresis; this mortality signal is fabricated, and ultrafiltration is not indicated on the basis of a modest creatinine rise during effective decongestion.
3. A 65-year-old woman with HFrEF has been on furosemide 80 mg twice daily for 14 months. She now presents with worsening peripheral edema despite medication adherence. Her eGFR is 44 mL/min/1.73m², albumin is normal, cardiac output is clinically adequate, and she is not on NSAIDs. Her physician diagnoses the braking phenomenon and adds metolazone 2.5 mg orally. Which of the following best describes the correct monitoring plan for the first 48 hours after metolazone initiation and explains why?
A) The only monitoring required is daily weight measurement and urine output, because metolazone acts exclusively at the distal convoluted tubule where no electrolyte transporters other than NCC are present; its addition to furosemide does not increase the risk of potassium or magnesium depletion beyond what furosemide alone was already producing
B) Serum electrolytes (potassium, magnesium, sodium) and creatinine should be checked within 6–12 hours of the first metolazone dose and daily thereafter; metolazone's NCC blockade dramatically amplifies the sodium load delivered to the collecting duct, intensifying Na-K exchange and potassium wasting beyond furosemide's baseline effect, and hypomagnesemia perpetuates hypokalemia by impairing renal potassium conservation — both electrolyte derangements can develop rapidly and reach dangerous levels within hours of the first combined dose
C) Monitoring can be deferred to a routine outpatient visit in 2 weeks because metolazone's onset of action is delayed by 48–72 hours due to the need for hepatic conversion to its active NCC-blocking metabolite; the diuretic synergy does not begin until this conversion is complete, providing adequate time for scheduled laboratory follow-up rather than urgent same-day monitoring
D) Only serum sodium requires urgent monitoring; the combination of furosemide and metolazone produces dilutional hyponatremia through simultaneous blockade of two urine-diluting segments (the thick ascending limb and distal convoluted tubule), but potassium depletion is self-limiting because the increased distal sodium delivery simultaneously upregulates the aldosterone-independent ROMK potassium secretion ceiling, preventing clinically significant hypokalemia
E) Blood pressure monitoring every 4 hours is the only urgent requirement; the primary risk from sequential nephron blockade is orthostatic hypotension from rapid intravascular volume depletion, and electrolyte derangements are a late finding that appears only after cumulative fluid losses exceed 3 liters — well beyond what a 2.5 mg metolazone dose can produce in the first 48 hours
ANSWER: B
Rationale:
Adding metolazone to furosemide for sequential nephron blockade requires urgent electrolyte monitoring because the combination can produce dramatic and rapidly developing electrolyte derangements. Metolazone's NCC blockade in the distal convoluted tubule prevents reclamation of the sodium that furosemide's NKCC2 blockade delivered distally — the two drugs together deliver a substantially greater sodium load to the cortical collecting duct than either drug alone. This amplified distal sodium delivery drives intensified Na-K exchange: sodium enters principal cells through ENaC, creating an electrochemical gradient that drives potassium secretion via ROMK into the tubular lumen. The net effect is potassium wasting that can be dramatically greater than furosemide alone was producing. Simultaneous magnesium losses occur because NKCC2 blockade impairs magnesium reabsorption in the thick ascending limb, and the amplified tubular flow augments magnesium washout. Critically, hypomagnesemia perpetuates hypokalemia: magnesium is required for basolateral Na-K-ATPase activity that maintains the intracellular potassium gradient, and magnesium deficiency impairs the renal potassium conservation mechanisms in the collecting duct. A patient can develop potassium of 2.8–3.0 mEq/L and magnesium of 1.2 mg/dL within 12–24 hours of the first metolazone dose — levels carrying arrhythmia risk in a patient with structurally abnormal myocardium. The standard of care is electrolytes and creatinine within 6–12 hours of the first dose.
Option A: Option A is incorrect: the distal convoluted tubule NCC blockade by metolazone does substantially increase potassium and magnesium wasting by amplifying the sodium load delivered to the collecting duct — the claim that no additional electrolyte risk exists beyond furosemide alone is clinically dangerous and incorrect.
Option C: Option C is incorrect: metolazone does not require hepatic conversion to an active metabolite; it is pharmacologically active as administered and the diuretic response begins within hours of the oral dose, not 48–72 hours later.
Option D: Option D is incorrect: ROMK potassium secretion does not have an upregulation ceiling that self-limits hypokalemia; amplified distal sodium delivery drives progressively greater potassium secretion without an automatic ceiling mechanism, and the statement is pharmacologically inaccurate.
Option E: Option E is incorrect: electrolyte derangements from metolazone + furosemide are an early, not late, finding and can develop within the first 6–12 hours; a 2.5 mg metolazone dose can produce very substantial urine output in a patient with braking phenomenon, making early monitoring essential.
4. A 61-year-old man with HFrEF (LVEF 32%, NYHA class II) was started on spironolactone 25 mg daily 3 months ago as part of GDMT. He now reports bilateral breast tenderness and early gynecomastia. His potassium is 4.5 mEq/L and eGFR is 54 mL/min/1.73m². Which of the following best explains the mechanism of this adverse effect and identifies the correct management?
A) The gynecomastia is caused by spironolactone-induced inhibition of CYP19A1 (aromatase), which converts androgens to estrogens in peripheral adipose tissue; by blocking aromatase, spironolactone paradoxically causes estrogen accumulation through substrate shunting to an alternative non-CYP19A1 estrogenic pathway; dose reduction to 12.5 mg daily typically resolves gynecomastia because aromatase inhibition is dose-dependent
B) The gynecomastia reflects spironolactone's direct agonist activity at the estrogen receptor in breast glandular tissue; unlike the mineralocorticoid receptor, the estrogen receptor is activated rather than blocked by spironolactone's lactone ring structure; switching to eplerenone resolves the problem because eplerenone's epoxide modification eliminates estrogen receptor agonism while preserving MR antagonism
C) The gynecomastia is a mechanism-based adverse effect of spironolactone's binding to androgen receptors in addition to the mineralocorticoid receptor; anti-androgenic activity in breast tissue reduces androgenic suppression of glandular proliferation, producing true gynecomastia; because this is receptor-based rather than dose-dependent at therapeutic doses, switching to eplerenone — which has high MR selectivity and minimal androgen receptor affinity — is the appropriate response, and the MRA therapy should be continued rather than discontinued
D) The gynecomastia is caused by spironolactone-induced upregulation of aromatase activity in Leydig cells, increasing peripheral androgen-to-estrogen conversion; dose reduction to 12.5 mg daily eliminates this aromatase effect because it occurs only above a pharmacological threshold that the lower dose does not reach; eplerenone does not upregulate aromatase and is therefore free of this adverse effect
E) Gynecomastia from spironolactone reflects accumulation of its active metabolite canrenone in breast adipose tissue, where canrenone acts as a direct estrogen receptor agonist at concentrations achievable with standard doses; switching to a lower dose of spironolactone (12.5 mg daily) reduces canrenone concentrations below the estrogen receptor activation threshold and is preferred over switching to eplerenone, which produces the same canrenone levels due to shared metabolic pathways
ANSWER: C
Rationale:
Spironolactone's gynecomastia is a classic mechanism-based adverse drug effect arising from its non-selective receptor binding profile. In addition to competitively blocking the mineralocorticoid receptor (its therapeutic target), spironolactone and its active metabolites bind androgen receptors with clinically meaningful affinity, acting as an androgen receptor antagonist. In male breast tissue, androgens normally suppress glandular proliferation; anti-androgenic blockade removes this suppression, allowing estrogen-driven glandular growth to dominate — producing true gynecomastia (glandular tissue enlargement rather than simple fat deposition) and associated breast tenderness. This mechanism was confirmed in the RALES trial, where gynecomastia or breast tenderness occurred in approximately 10% of men on spironolactone versus approximately 1% on placebo. Because the mechanism is receptor-binding at therapeutic concentrations rather than a dose-dependent pharmacokinetic effect, dose reduction often does not fully resolve the problem. The correct response is to switch to eplerenone, which was structurally designed to have high selectivity for the mineralocorticoid receptor with minimal androgen receptor and progesterone receptor affinity. Clinical data confirm that eplerenone produces gynecomastia at rates comparable to placebo. Importantly, the underlying HFrEF indication for MRA therapy (NYHA class II, LVEF 32%, on GDMT) remains strong — the drug class should be continued, not abandoned.
Option A: Option A is incorrect: spironolactone does not inhibit CYP19A1 (aromatase); its gynecomastia mechanism is androgen receptor antagonism, not altered androgen-to-estrogen conversion via aromatase inhibition.
Option B: Option B is incorrect: spironolactone is not an estrogen receptor agonist; its affinity is for androgen receptors and progesterone receptors (as antagonist/partial agonist), not estrogen receptors; and eplerenone's structural modification eliminates sex hormone receptor activity broadly, not specifically estrogen receptor agonism.
5. A 57-year-old woman with HFrEF (LVEF 30%, NYHA class II) on sacubitril/valsartan and carvedilol asks her cardiologist why both spironolactone and eplerenone are mentioned as options. She has no history of endocrine side effects and no prior MI. Her potassium is 4.3 mEq/L and eGFR is 61 mL/min/1.73m². Which of the following best explains the evidence base distinguishing the two agents and the most appropriate choice for this patient?
A) Spironolactone is preferred in this patient because RALES demonstrated a 30% relative reduction in all-cause mortality specifically in NYHA class II patients on modern GDMT including sacubitril/valsartan; eplerenone's evidence base (EPHESUS, EMPHASIS-HF) does not include patients on ARNI therapy, so its efficacy cannot be assumed in this patient
B) Eplerenone is the only guideline-approved MRA for women with HFrEF because RALES enrolled predominantly men and its results cannot be extrapolated to women; EMPHASIS-HF included a balanced sex enrollment and provides the evidence base for eplerenone as the preferred agent specifically in female HFrEF patients
C) The choice between spironolactone and eplerenone in this patient is determined primarily by cost: spironolactone is generic and substantially less expensive, while eplerenone carries a brand-name premium; AHA/ACC/HFSA guidelines recommend initiating spironolactone first and switching to eplerenone only if endocrine side effects develop, making spironolactone the default first-line MRA in all patients without a prior MI
D) Spironolactone has stronger trial evidence for mortality reduction in chronic HFrEF: RALES demonstrated a 30% relative risk reduction, while EMPHASIS-HF with eplerenone showed only a 37% reduction in a composite endpoint (not all-cause mortality); in patients without a specific indication for eplerenone (post-MI), spironolactone's mortality data make it the preferred agent
E) Both agents block the mineralocorticoid receptor with comparable MR selectivity difference — spironolactone in RALES (NYHA III–IV on older GDMT) and eplerenone in EMPHASIS-HF (NYHA II on modern GDMT including ACE inhibitor or ARB and beta-blocker) — making EMPHASIS-HF the more directly applicable trial for this NYHA class II patient on modern GDMT; however, either agent is guideline-appropriate given acceptable renal function and potassium, with eplerenone preferred if endocrine side effects are a concern and spironolactone preferred if cost is a limiting factor
ANSWER: E
Rationale:
Both spironolactone and eplerenone have class I guideline recommendations for HFrEF with LVEF of 35% or less, and neither is categorically superior for a patient like this one — the choice is individualized based on tolerability, trial population applicability, and practical factors. The key distinction between the two trials is the population studied: RALES (spironolactone) enrolled patients with severe symptoms (NYHA class III–IV) on a GDMT backbone that predated routine beta-blocker use and did not include ARNI; EMPHASIS-HF (eplerenone) enrolled patients with mild symptoms (NYHA class II) on contemporary GDMT including ACE inhibitor or ARB and beta-blocker — a background more analogous to this patient on sacubitril/valsartan and carvedilol. For this NYHA class II patient on modern GDMT, EMPHASIS-HF is the more directly applicable trial. However, both agents are guideline-appropriate because guidelines support MRA use across NYHA class II–IV on the strength of the combined evidence base. The practical selection principles are: eplerenone is preferred when endocrine side effects (gynecomastia in men, menstrual irregularities in women) are anticipated or have occurred; spironolactone is preferred when cost or formulary access is a limiting factor, given its generic availability. For a post-MI patient with LV dysfunction, eplerenone has specific EPHESUS evidence and is the preferred agent in that indication.
Option A: Option A is incorrect: RALES enrolled NYHA class III–IV patients, not class II, and was conducted before sacubitril/valsartan existed; RALES is not the applicable trial for this patient's indication.
Option B: Option B is incorrect: there is no guideline restriction of eplerenone to women or spironolactone to men; both agents are approved regardless of sex.
Option C: Option C is incorrect: while cost considerations are valid practical factors, guidelines do not establish spironolactone as the mandatory default with eplerenone reserved only for side-effect cases; eplerenone is also a guideline-supported first-line option.
Option D: Option D is incorrect: comparing RALES's 30% all-cause mortality reduction to EMPHASIS-HF's composite endpoint reduction is not a valid basis for declaring spironolactone's mortality evidence superior — the trials studied different populations with different background therapy, and the EMPHASIS-HF composite included cardiovascular death, making the comparison misleading.
6. A 66-year-old man is on day 8 following an anterior STEMI (ST-elevation myocardial infarction) treated with primary PCI (percutaneous coronary intervention). His post-MI echocardiogram shows LVEF of 36% with anterior wall hypokinesis. He has mild dyspnea on exertion (NYHA class II). Current medications include aspirin, ticagrelor, metoprolol succinate 25 mg daily, and ramipril 5 mg daily. His potassium is 4.4 mEq/L, creatinine is 1.1 mg/dL (eGFR 68 mL/min/1.73m²), and he does not have diabetes. The cardiology team discusses adding eplerenone. Which of the following best evaluates whether this patient meets EPHESUS eligibility criteria and identifies the appropriate next step?
A) This patient meets the core EPHESUS eligibility criteria: EPHESUS enrolled patients with acute MI complicated by LV dysfunction (LVEF 40% or less) and either symptomatic heart failure or diabetes, initiating eplerenone 3–14 days post-MI on background ACE inhibitor and beta-blocker; this patient has LVEF 36%, symptomatic HF (NYHA class II dyspnea), is on day 8 post-MI, and has acceptable renal function and potassium — eplerenone should be initiated at 25 mg daily with repeat potassium and creatinine in 1 week
B) This patient does not meet EPHESUS criteria because EPHESUS required both symptomatic heart failure AND diabetes as dual enrollment criteria; since this patient has symptomatic HF but not diabetes, he meets only one of the two required conditions and eplerenone is not indicated based on EPHESUS evidence alone
C) Eplerenone should be deferred until at least 30 days post-MI because EPHESUS demonstrated that early initiation (within 14 days of MI) was associated with a paradoxical increase in sudden cardiac death from eplerenone-induced electrolyte instability during the acute post-MI repolarization vulnerability period; benefit emerged only after the first month of therapy
D) This patient does not meet EPHESUS criteria because his LVEF of 36% is above the 30% maximum threshold used for enrollment; EPHESUS restricted enrollment to patients with LVEF 30% or less to ensure a sufficiently high-risk population in whom MRA benefit could be demonstrated; patients with LVEF between 30% and 40% were excluded and should receive spironolactone (studied across the full 40% or less range in RALES) rather than eplerenone
E) Eplerenone is contraindicated in this patient because he is already receiving ramipril; the combination of an ACE inhibitor and an MRA within 14 days of MI is associated with a clinically unacceptable rate of acute renal failure in the post-infarction kidney, which is uniquely vulnerable to RAAS blockade due to infarct-related renal microemboli; EPHESUS specifically excluded patients on ACE inhibitors at the time of randomization
ANSWER: A
Rationale:
This patient is a precise match for the EPHESUS trial population. EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study, Pitt et al., N Engl J Med, 2003) enrolled 6,632 patients with acute MI complicated by LV dysfunction (LVEF of 40% or less) and either symptomatic heart failure or diabetes mellitus — the two enrollment pathways were disjunctive (either/or), not conjunctive (both required). Randomization occurred 3–14 days post-MI, with background therapy of ACE inhibitor and beta-blocker. This patient satisfies each criterion: LVEF 36% (at or below 40%), symptomatic HF (NYHA class II exertional dyspnea), day 8 post-MI (within the 3–14 day window), on ramipril (ACE inhibitor) and metoprolol succinate (beta-blocker), potassium 4.4 mEq/L (below 5.0 mEq/L), and eGFR 68 mL/min/1.73m² (well above 30 mL/min/1.73m²). The EPHESUS protocol initiated eplerenone at 25 mg daily, titrated to 50 mg daily at 4 weeks if potassium remained below 5.0 mEq/L. Close monitoring (repeat potassium and creatinine within 1 week) is standard given the combined RAAS blockade.
Option B: Option B is incorrect: EPHESUS used an either/or enrollment criterion — symptomatic HF or diabetes; not both were required. This patient's symptomatic HF alone satisfies the enrollment criterion.
Option C: Option C is incorrect: EPHESUS did not show a paradoxical increase in sudden cardiac death with early initiation; the trial demonstrated significant mortality benefit with eplerenone initiated 3–14 days post-MI, and early MRA initiation in the post-MI period is the guideline-recommended approach based on EPHESUS.
Option D: Option D is incorrect: EPHESUS enrolled patients with LVEF of 40% or less — not 30% or less; the 40% threshold is the correct EPHESUS criterion, and this patient's LVEF of 36% falls within the eligible range.
Option E: Option E is incorrect: EPHESUS was specifically conducted on background ACE inhibitor and beta-blocker therapy — ACE inhibitor use was a requirement for enrollment in EPHESUS, not an exclusion criterion; the combination of ACE inhibitor and eplerenone was tested and found safe and effective in the trial.
7. A 72-year-old woman with HFrEF is receiving IV furosemide 160 mg twice daily plus metolazone 5 mg daily for diuretic resistance. She has lost 7 kg over 5 days. Her arterial blood gas now shows pH 7.52, PCO₂ 48 mmHg, bicarbonate 38 mEq/L. Which of the following best explains the mechanism producing this acid-base disturbance and identifies the appropriate clinical response?
A) The elevated pH and bicarbonate reflect a primary respiratory alkalosis from furosemide-induced prostaglandin release stimulating the central respiratory center; the compensatory CO₂ retention (PCO₂ 48 mmHg) confirms the respiratory origin; the clinical response is to reduce the furosemide dose to below the prostaglandin-stimulating threshold and switch to torsemide, which has lower prostaglandin-stimulating activity
B) Aggressive loop diuretic therapy produces metabolic alkalosis through two mechanisms: urinary chloride loss (furosemide delivers sodium and chloride to the collecting duct where chloride is lost in urine, reducing serum chloride and shifting the bicarbonate-chloride equilibrium toward bicarbonate retention) and volume contraction alkalosis (reduced extracellular volume activates aldosterone and increases proximal tubular bicarbonate reabsorption, sustaining the alkalosis); the CO₂ retention is appropriate respiratory compensation; the clinical response is to ensure adequate chloride repletion and reassess the diuretic dose once euvolemia is approached
C) The acid-base picture reflects primary respiratory acidosis with metabolic compensation; furosemide's NKCC2 blockade in the thick ascending limb impairs CO₂ excretion by inhibiting the carbonic anhydrase activity that normally facilitates CO₂ diffusion from tubular cells into the peritubular capillary; the resulting systemic CO₂ accumulation elevates bicarbonate as a compensatory buffer; the clinical response is to switch to bumetanide, which lacks NKCC2-associated carbonic anhydrase binding
D) The elevated bicarbonate reflects furosemide-induced activation of the proximal tubule H-K-ATPase, which excretes hydrogen ions into the tubular lumen in exchange for potassium; the net effect is systemic proton loss causing metabolic alkalosis; adding spironolactone reverses this mechanism by blocking H-K-ATPase in the collecting duct and restoring normal hydrogen ion balance
E) The acid-base disturbance is a mixed respiratory and metabolic alkalosis caused by furosemide-induced hypophosphatemia; phosphate depletion impairs the intracellular phosphate buffer system in red blood cells, reducing 2,3-DPG production and shifting the oxyhemoglobin dissociation curve leftward; the resulting tissue hyperoxia suppresses the hypoxic respiratory drive and causes CO₂ accumulation with secondary bicarbonate elevation
ANSWER: B
Rationale:
This patient has metabolic alkalosis (pH 7.52, bicarbonate 38 mEq/L) with appropriate respiratory compensation (CO₂ retention to 48 mmHg — the expected PCO₂ compensation for metabolic alkalosis is approximately 0.7 × [HCO₃ rise], consistent with the values shown). Aggressive loop diuretic therapy generates metabolic alkalosis through two well-established mechanisms operating simultaneously. First, urinary chloride wasting: furosemide's NKCC2 blockade in the thick ascending limb blocks cotransport of Na⁺, K⁺, and 2Cl⁻, delivering large chloride loads to the distal nephron; the increased urinary chloride excretion reduces serum chloride, and because electrical neutrality must be maintained in the extracellular fluid, bicarbonate (the major alternative anion) is retained — shifting the bicarbonate-chloride equilibrium toward bicarbonate accumulation. Second, volume contraction alkalosis: aggressive diuresis reduces extracellular fluid volume, activating the renin-angiotensin-aldosterone system; aldosterone promotes both distal tubule sodium reabsorption and hydrogen ion secretion (via H-ATPase in intercalated cells), generating new bicarbonate; simultaneously, volume contraction increases the fractional reabsorption of bicarbonate in the proximal tubule, sustaining the alkalosis. The alkalosis is self-perpetuating unless chloride is repleted, because the kidney cannot excrete bicarbonate without adequate chloride. The clinical response includes reassessing diuretic dose as the patient approaches euvolemia, ensuring chloride repletion (typically through potassium chloride supplementation), and monitoring electrolytes closely.
Option A: Option A is incorrect: the acid-base picture is metabolic alkalosis with respiratory compensation — not a primary respiratory alkalosis; the PCO₂ of 48 mmHg is elevated (not reduced) confirming metabolic rather than respiratory origin.
Option C: Option C is incorrect: furosemide does not impair CO₂ excretion through NKCC2-carbonic anhydrase binding; NKCC2 is not a carbonic anhydrase; the acid-base picture here is metabolic alkalosis, not primary respiratory acidosis.
Option D: Option D is incorrect: furosemide does not activate the proximal tubule H-K-ATPase; metabolic alkalosis from loop diuretics is generated by chloride wasting and volume contraction, not by direct H-K-ATPase activation; spironolactone does not block H-K-ATPase.
Option E: Option E is incorrect: furosemide-induced hypophosphatemia causing 2,3-DPG depletion and CO₂ accumulation is a fabricated mechanism; loop diuretics do not produce clinically significant hypophosphatemia as a primary effect, and the described pathway does not represent a recognized cause of metabolic alkalosis.
8. A 74-year-old man with HFrEF (LVEF 27%) has been on furosemide 80 mg twice daily and spironolactone 25 mg daily for 18 months. He presents with worsening edema despite compliance. Review reveals he started naproxen 500 mg twice daily for knee pain 6 weeks ago. Albumin is normal, cardiac output is clinically adequate, and creatinine is 1.4 mg/dL (eGFR 48 mL/min/1.73m²). Which of the following best identifies the most immediately reversible mechanism of his diuretic resistance and the correct first intervention?
A) The most immediately reversible mechanism is the braking phenomenon from 18 months of furosemide use; compensatory distal tubule NCC upregulation is the dominant cause of resistance at this duration of therapy, and the correct first intervention is to add metolazone 2.5 mg daily to overcome the hypertrophied distal convoluted tubule NCC before addressing other contributing factors
B) The most immediately reversible mechanism is MRA-induced suppression of aldosterone-driven distal sodium reabsorption, which paradoxically impairs the electrochemical gradient for furosemide to act; the correct first intervention is to temporarily hold spironolactone for 2 weeks to restore aldosterone-driven distal tubular sodium reabsorption and re-establish the pharmacological target for furosemide's distal sodium delivery effect
C) The most immediately reversible mechanism is NSAID-mediated prostaglandin synthesis inhibition, which reduces renal prostaglandin-driven vasodilation, decreases renal blood flow and furosemide delivery to OAT1/OAT3 secretion sites, and blunts the early prostaglandin-mediated venodilatory benefit of furosemide; the correct first intervention is to discontinue naproxen immediately and substitute acetaminophen, as NSAIDs are contraindicated in HFrEF and removing this mechanism costs nothing and carries no risk
D) The most immediately reversible mechanism is furosemide-induced contraction of extracellular fluid volume, which activates renin-angiotensin-aldosterone and partially offsets diuresis through aldosterone-driven collecting duct sodium retention; the correct first intervention is to hold furosemide for 48 hours to allow the RAAS to reset and then resume at a lower dose, which will produce greater net natriuresis by avoiding the neurohormonal blunting of diuretic effect
E) The most immediately reversible mechanism is reduced delivery of furosemide to OAT1/OAT3 due to the 18-month duration of therapy causing progressive renal tubular OAT1/OAT3 expression downregulation; chronic loop diuretic exposure reduces proximal tubular secretory capacity through transporter internalization, and the correct first intervention is a 2-week furosemide holiday to restore OAT transporter expression before resuming at the prior dose
ANSWER: C
Rationale:
This patient has at least two contributing mechanisms of diuretic resistance — the braking phenomenon from 18 months of furosemide (NCC upregulation) and NSAID-mediated prostaglandin inhibition from 6 weeks of naproxen — but the most immediately reversible mechanism with the most favorable risk-benefit ratio is the NSAID effect. NSAIDs inhibit COX (cyclooxygenase) enzymes, blocking prostaglandin synthesis and thereby: (1) reducing renal prostaglandin-mediated vasodilation, which decreases renal blood flow and impairs OAT1/OAT3-mediated furosemide delivery to the tubular lumen; (2) blunting the early prostaglandin-mediated venodilatory component of IV furosemide action; and (3) in patients with neurohormonal activation (as in HFrEF), removing a critical compensatory mechanism for maintaining GFR. NSAIDs are formally contraindicated in HFrEF — they worsen sodium retention, can precipitate acute decompensation, and interfere with the efficacy of diuretics and RAAS inhibitors. Discontinuing naproxen and substituting acetaminophen is the correct, immediate, and zero-risk first intervention: it costs nothing, removes a contraindicated drug, and may substantially restore furosemide responsiveness without adding any new medication. The braking phenomenon is real and may require sequential nephron blockade, but that intervention (metolazone) carries significant electrolyte risks and should come after removing the reversible NSAID contribution first.
Option A: Option A is incorrect: while the braking phenomenon is a likely contributor after 18 months, addressing it with metolazone before removing the NSAID is the wrong sequence; the NSAID is the most immediately reversible mechanism and should be removed first.
Option B: Option B is incorrect: spironolactone does not impair furosemide's mechanism by suppressing aldosterone-driven distal reabsorption; holding spironolactone removes a guideline-recommended survival benefit with no rational pharmacological basis for improving diuretic response — this option is pharmacologically incoherent.
Option D: Option D is incorrect: holding furosemide for 48 hours to "reset" the RAAS will worsen fluid overload without producing the described benefit; RAAS activation during diuretic therapy is addressed by optimizing GDMT, not by diuretic holidays.
Option E: Option E is incorrect: chronic furosemide use does not cause OAT1/OAT3 transporter internalization or progressive secretory capacity downregulation — this is a fabricated mechanism; OAT transporter expression is not down-regulated by chronic loop diuretic exposure in any clinically established way.
9. A 68-year-old woman with HFpEF (LVEF 58%, NYHA class II, hospitalized for HF 5 months ago) asks her cardiologist whether spironolactone will reduce her risk of future hospitalization. Her potassium is 4.2 mEq/L and eGFR is 52 mL/min/1.73m². Which of the following best represents an accurate and balanced evidence-based response to her question?
A) Spironolactone has a class I recommendation in HFpEF based on TOPCAT, which demonstrated a statistically significant reduction in HF hospitalization in the overall trial population; her prior hospitalization and NYHA class II symptoms place her in the highest-benefit subgroup identified in TOPCAT, and the data strongly support initiating spironolactone at 25 mg daily
B) Spironolactone should not be used in HFpEF under any circumstances because TOPCAT demonstrated a non-significant trend toward harm in the overall population and a statistically significant increase in hyperkalemia-related hospitalizations in the Americas subgroup; current AHA/ACC/HFSA guidelines have removed MRAs from the HFpEF treatment algorithm entirely
C) Spironolactone carries a class I recommendation in HFpEF for patients with prior hospitalization specifically, based on a pre-specified subgroup analysis in TOPCAT showing significant benefit in this population; patients without prior hospitalization receive a class IIb recommendation, and her hospitalization history upgrades her recommendation to class I
D) The evidence for spironolactone in HFpEF is genuinely uncertain: TOPCAT's overall primary endpoint (cardiovascular death, aborted cardiac arrest, or HF hospitalization) did not reach statistical significance (HR 0.89; p=0.14), and the trial is methodologically controversial because patients in Russia and Georgia likely did not receive active drug; Americas subgroup analyses suggest possible benefit in HF hospitalization; current guidelines give MRAs a class IIb recommendation in symptomatic HFpEF — meaning it is reasonable to consider, not clearly indicated — and her prior hospitalization, acceptable renal function, and potassium make her a reasonable candidate if she and her physician decide the potential benefit justifies initiation
E) Spironolactone is not appropriate for this patient because HFpEF with LVEF above 55% was excluded from TOPCAT; the trial enrolled only patients with LVEF between 45% and 55%, and her LVEF of 58% places her outside the studied population; eplerenone, which was studied at higher LVEF values in EMPHASIS-HF extension analyses, is the preferred MRA for HFpEF with LVEF above 55%
ANSWER: D
Rationale:
Counseling this patient honestly about spironolactone in HFpEF requires accurately conveying both the potential signal of benefit and the genuine uncertainty in the evidence. TOPCAT randomized 3,445 patients with HFpEF (LVEF 45% or greater) to spironolactone 15–45 mg daily versus placebo. The overall primary composite endpoint — cardiovascular death, aborted cardiac arrest, or HF hospitalization — did not reach statistical significance: HR 0.89 (95% CI 0.77–1.04; p=0.14). The trial is methodologically controversial because plasma canrenone concentrations (a spironolactone adherence biomarker) were near zero in patients from Russia and Georgia, raising serious concern that those patients did not receive active drug. When restricted to patients from the Americas, spironolactone showed a significant reduction in HF hospitalization. The current AHA/ACC/HFSA 2022 guidelines give MRAs a class IIb recommendation in symptomatic HFpEF — meaning "may be reasonable to consider" — not a class I recommendation. This patient is a reasonable candidate given her prior hospitalization, NYHA class II symptoms, acceptable potassium, and eGFR above the 30 mL/min/1.73m² threshold; but shared decision-making is appropriate given the uncertain evidence. An honest answer to her question is that the evidence suggests a possible but not proven benefit, that guidelines consider it reasonable to try, and that the risks (primarily hyperkalemia) are manageable with monitoring.
Option A: Option A is incorrect: TOPCAT did not demonstrate a statistically significant reduction in the overall primary endpoint; the recommendation is class IIb, not class I.
Option B: Option B is incorrect: TOPCAT did not show a trend toward harm or a significant increase in hyperkalemia hospitalizations in the Americas subgroup; MRAs remain a class IIb option in HFpEF and have not been removed from the treatment algorithm.
Option C: Option C is incorrect: there is no pre-specified subgroup analysis in TOPCAT that upgrades the recommendation to class I for patients with prior hospitalization; prior hospitalization was one of two enrollment pathways in TOPCAT, not a subgroup with a distinct class I recommendation.
Option E: Option E is incorrect: TOPCAT enrolled patients with LVEF of 45% or greater — this patient's LVEF of 58% falls within the enrolled range; there is no LVEF upper limit exclusion in TOPCAT, and no EMPHASIS-HF extension analysis specifically studying higher LVEF ranges exists.
10. A 69-year-old man with HFrEF (LVEF 33%, NYHA class II) is on lisinopril 10 mg daily, carvedilol 12.5 mg twice daily, and spironolactone 25 mg daily. Routine labs show potassium 5.7 mEq/L and creatinine 1.6 mg/dL (eGFR 42 mL/min/1.73m²). He is asymptomatic and his ECG shows no hyperkalemic changes. Which of the following best describes the stepwise management of his hyperkalemia while preserving MRA therapy where possible?
A) Potassium of 5.7 mEq/L in a patient on MRA therapy mandates permanent discontinuation of spironolactone; reinitiating an MRA after a hyperkalemic episode in a patient with eGFR below 45 mL/min/1.73m² carries a greater than 40% risk of recurrent dangerous hyperkalemia within 90 days, and AHA/ACC/HFSA guidelines recommend against MRA rechallenge in this renal function range once hyperkalemia has occurred
B) The first step is to hold lisinopril permanently and initiate hydralazine-isosorbide dinitrate as an ACE inhibitor-free RAAS substitute; spironolactone should be continued at the current dose because the ACE inhibitor is the dominant cause of hyperkalemia in this combination and its removal will restore potassium to the target range without requiring any change to spironolactone
C) Sodium polystyrene sulfonate (Kayexalate) should be administered immediately at 30 g orally to acutely lower potassium, followed by dietary potassium restriction to less than 1 g daily indefinitely; spironolactone and lisinopril can be continued at current doses because chronic potassium binder therapy is sufficient to maintain safe potassium levels regardless of ongoing RAAS blockade
D) The ECG should be checked immediately for hyperkalemic changes; if the ECG is normal (as in this patient), the potassium of 5.7 mEq/L should be rechecked once to confirm it is not a laboratory artifact (hemolysis, delayed processing), and if confirmed, the appropriate response is emergency IV calcium gluconate administration to stabilize cardiac membranes before any diuretic or dietary intervention
E) A stepwise approach is appropriate: first confirm the potassium by repeat measurement (hemolysis can falsely elevate K⁺); review and eliminate contributing factors (dietary potassium load, concurrent potassium supplements, NSAIDs, trimethoprim); reduce or hold spironolactone temporarily (reduce to 12.5 mg or hold) while maintaining lisinopril if possible; consider a potassium binder (patiromer or sodium zirconium cyclosilicate [SZC]) to enable MRA continuation in a patient with clear GDMT indication; recheck potassium in 5–7 days with the goal of reaching below 5.0 mEq/L before reintroducing or uptitrating spironolactone
ANSWER: E
Rationale:
Potassium of 5.7 mEq/L in a patient on MRA plus ACE inhibitor requires systematic evaluation and management aimed at preserving MRA therapy where possible, because this patient has a clear class I indication (HFrEF, LVEF 33%, NYHA class II) and discontinuing MRA therapy removes a survival benefit. The stepwise approach begins with confirmation: hemolysis, prolonged sample transport, or delayed processing can falsely elevate potassium, and a spurious result should not drive medication changes — particularly in an asymptomatic patient with a normal ECG. If the elevation is confirmed, contributing factors are reviewed: excessive dietary potassium, potassium supplements, NSAIDs (which impair renal potassium excretion), trimethoprim (which blocks ENaC like amiloride), and any other RAAS-interacting agents. Reducing spironolactone (from 25 mg to 12.5 mg daily) or temporarily holding it allows potassium to fall while the ACE inhibitor is maintained — the ACE inhibitor's neurohormonal benefit in HFrEF also supports its preservation. Potassium binders (patiromer or SZC) have emerged as tools specifically enabling MRA use in patients who develop hyperkalemia, with clinical trial evidence (AMBER, DIAMOND trials) showing they allow MRA continuation in patients who would otherwise require dose reduction or discontinuation. Recheck in 5–7 days with a target below 5.0 mEq/L before resuming or uptitrating.
Option A: Option A is incorrect: AHA/ACC/HFSA guidelines do not recommend permanent MRA discontinuation after a single hyperkalemic episode at eGFR above 30 mL/min/1.73m²; cautious dose reduction, contributing factor elimination, and rechallenge are the standard approach.
Option B: Option B is incorrect: permanently discontinuing lisinopril and switching to hydralazine-isosorbide dinitrate is an extreme response to a hyperkalemic episode that does not require RAAS elimination; hydralazine-isosorbide is a second-line option for patients who cannot tolerate any RAAS inhibitor, not a routine substitution for hyperkalemia management.
Option C: Option C is incorrect: sodium polystyrene sulfonate (Kayexalate) is not indicated for asymptomatic chronic hyperkalemia at 5.7 mEq/L; it is primarily used for acute severe hyperkalemia and has significant GI side effects; modern potassium binders (patiromer, SZC) have a more favorable safety profile and are preferred for chronic management.
Option D: Option D is incorrect: while an ECG is appropriate to check for hyperkalemic changes (and was already noted as normal in this patient), IV calcium gluconate is indicated for severe symptomatic hyperkalemia with ECG changes — not for asymptomatic K⁺ 5.7 mEq/L with a normal ECG; immediate calcium administration in this scenario is unnecessary and not indicated.
11. A 63-year-old woman with chronic HFrEF (LVEF 35%) is being discharged after an HF hospitalization. Her cardiologist switches her from furosemide 80 mg daily to torsemide 20 mg daily. She asks why the drug was changed and whether the new drug is stronger. Which of the following best explains the pharmacokinetic rationale for this switch and correctly addresses her question about potency?
A) Torsemide is stronger than furosemide on a milligram-per-milligram basis because it has a higher intrinsic affinity for NKCC2; the 20 mg torsemide dose produces a greater peak natriuresis than 80 mg furosemide, which is why dose reduction was appropriate at discharge; TRANSFORM-HF confirmed that torsemide's greater potency translates into significantly fewer rehospitalizations compared to furosemide at equivalent doses
B) Torsemide 20 mg is approximately equivalent in natriuretic effect to furosemide 80 mg daily (the standard potency ratio is 40 mg furosemide ≈ 20 mg torsemide); the reason for switching is pharmacokinetic: torsemide has oral bioavailability of approximately 80–90% (consistent across patients) compared to furosemide's highly variable 10–100% average of 50%; torsemide also has a longer duration of action (6–8 hours versus 4–6 hours), providing more predictable and sustained diuresis in outpatient maintenance — both properties reduce the day-to-day variability in fluid balance that contributes to HF rehospitalization
C) The switch from furosemide 80 mg to torsemide 20 mg represents a dose reduction intended to reduce diuretic intensity at discharge; torsemide is used at one-quarter of the furosemide dose specifically to prevent over-diuresis during the vulnerable post-discharge period when patients are less closely monitored; TRANSFORM-HF confirmed that post-discharge torsemide at reduced doses prevents the renal complications associated with continuing high furosemide doses after hospitalization
D) Torsemide is preferred after hospitalization because it undergoes complete renal elimination without hepatic metabolism, allowing dose titration based solely on creatinine clearance without the inter-individual pharmacokinetic variability introduced by hepatic CYP enzyme polymorphisms that affect furosemide metabolism; the 20 mg torsemide dose was selected based on her eGFR using the renal dosing nomogram established in TRANSFORM-HF
E) The switch is based on evidence that torsemide significantly reduces all-cause mortality compared to furosemide in post-hospitalization HF patients; TRANSFORM-HF demonstrated a hazard ratio of 0.79 (p=0.02) favoring torsemide for 12-month all-cause mortality, establishing torsemide as the preferred maintenance loop diuretic after HF hospitalization per AHA/ACC/HFSA 2022 guidelines
ANSWER: B
Rationale:
The pharmacokinetic rationale for preferring torsemide over furosemide in outpatient maintenance therapy is well established and should be communicated clearly to the patient. First, regarding dose equivalence: torsemide 20 mg is approximately equivalent in natriuretic effect to furosemide 40 mg based on the standard loop diuretic potency ratio (furosemide 40 mg ≈ torsemide 20 mg ≈ bumetanide 1 mg); switching from furosemide 80 mg daily to torsemide 20 mg daily is therefore a dose-equivalent substitution, not a dose reduction or intensification — the patient is receiving approximately the same natriuretic effect. Second, the reason for switching is pharmacokinetic, not potency: torsemide's oral bioavailability is approximately 80–90% and is consistent across patients and clinical states, compared to furosemide's highly variable 10–100% (average ~50%); this means torsemide produces predictable and reproducible plasma concentrations after each oral dose, whereas furosemide patients can experience substantial day-to-day variability in diuretic effect from the same dose. Torsemide also has a longer duration of action, potentially providing more complete 24-hour sodium balance coverage. The TRANSFORM-HF trial confirmed that torsemide and furosemide have equivalent all-cause mortality and rehospitalization outcomes, but some analyses favored torsemide for quality-of-life and diuretic-related side effects. The drug is not "stronger" — it is more pharmacokinetically reliable at an equivalent dose.
Option A: Option A is incorrect: torsemide does not have greater intrinsic NKCC2 affinity than furosemide on a milligram basis (the standard potency ratio makes them equivalent at the doses prescribed); and TRANSFORM-HF did not demonstrate significantly fewer rehospitalizations with torsemide.
Option C: Option C is incorrect: the switch from furosemide 80 mg to torsemide 20 mg is a dose-equivalent switch, not a deliberate dose reduction; TRANSFORM-HF did not establish a post-discharge reduced-dose torsemide protocol.
Option D: Option D is incorrect: furosemide does not undergo significant hepatic CYP enzyme metabolism (it is predominantly renally eliminated as unchanged drug), and there is no eGFR-based torsemide dosing nomogram from TRANSFORM-HF.
Option E: Option E is incorrect: TRANSFORM-HF did not demonstrate a significant all-cause mortality reduction with torsemide (HR 1.02; p=0.82); there is no AHA/ACC/HFSA class I guideline recommendation establishing torsemide as the post-hospitalization preferred agent based on mortality evidence.
12. A 77-year-old man with HFrEF is receiving IV furosemide for acute decompensation. Over 72 hours he has lost 5 kg, his JVP (jugular venous pressure) has decreased from 14 cm to 8 cm H₂O, and his dyspnea has resolved. His creatinine has risen from 1.0 to 1.4 mg/dL. Blood pressure is 114/68 mmHg. Extremities are warm and urine output is 80–120 mL/hour. The intern asks whether to reduce the furosemide dose. Which of the following best applies the concept of acceptable worsening renal function (WRF) to this clinical scenario?
A) This clinical picture is consistent with acceptable WRF during effective decongestion: the patient has achieved meaningful fluid removal (5 kg, JVP improving from 14 to 8 cm), resolved dyspnea, and maintained hemodynamic stability without signs of hypoperfusion (warm extremities, normal blood pressure, adequate urine output); post-hoc analyses of HF trials demonstrate that persistent congestion at discharge is a stronger predictor of 30-day readmission than a modest in-hospital creatinine rise during effective diuresis — continuing diuresis while monitoring is appropriate
B) Any creatinine rise above 0.3 mg/dL during IV diuresis represents nephrotoxic acute tubular injury from loop diuretics and requires immediate dose reduction; furosemide should be reduced by 50% and oral fluids encouraged to flush the tubular nephrotoxic metabolites that accumulate during aggressive IV dosing
C) The clinical picture indicates that this patient has been over-diuresed below his optimal filling pressure; the improvement in JVP from 14 to 8 cm H₂O and the creatinine rise confirm that ventricular filling pressure has been reduced below the Starling curve plateau, and further diuresis will reduce cardiac output; furosemide should be stopped and IV colloid administered to restore filling pressure to the 12–14 cm H₂O target range
D) While the clinical picture appears consistent with effective decongestion, the creatinine rise from 1.0 to 1.4 mg/dL (40% increase) exceeds the 20% creatinine rise threshold that AHA/ACC/HFSA guidelines specify as the maximum acceptable WRF during in-hospital diuresis; above this threshold, guidelines mandate furosemide dose reduction regardless of the volume status assessment, to comply with the nephroprotective protocol established in the CARRESS-HF trial
E) The warm extremities and adequate urine output confirm that this is acceptable WRF, but the improving JVP indicates that the patient has reached euvolemia; per AHA/ACC/HFSA 2022 guidelines, IV furosemide must be transitioned to oral furosemide immediately once JVP reaches below 10 cm H₂O, because continuing IV therapy beyond this point converts the diuresis from therapeutic to nephrotoxic regardless of volume status
ANSWER: A
Rationale:
This scenario illustrates the clinically important principle of acceptable WRF during effective decongestion. The patient's clinical picture has all the features of appropriate diuresis with an expected and acceptable renal response: he has lost 5 kg, JVP has improved from 14 to 8 cm H₂O (still mildly elevated at 8 cm — he is not yet at euvolemia), dyspnea has resolved, blood pressure is stable at 114/68 mmHg, extremities are warm (no hypoperfusion), and urine output of 80–120 mL/hour is appropriate and not oliguria. The creatinine rise of 0.4 mg/dL is modest and occurred in the context of effective volume removal from the correct compartment. Post-hoc analyses of multiple large HF registries and trial datasets have consistently demonstrated that in-hospital WRF during effective decongestion does not worsen 30-day or 90-day outcomes — and that patients who leave the hospital still congested (elevated JVP, persistent edema, dyspnea) have significantly higher 30-day readmission rates than patients who achieved complete decongestion even with a modest creatinine rise. This patient still has a mildly elevated JVP (8 cm H₂O) and has not yet achieved complete decongestion; continuing diuresis while monitoring creatinine and clinical volume status is the appropriate evidence-based response.
Option B: Option B is incorrect: loop diuretics are not directly nephrotoxic through tubular metabolite accumulation; the creatinine rise here reflects reduced GFR from volume removal (acceptable WRF), not drug toxicity — and the 0.3 mg/dL threshold for mandatory dose reduction is not a guideline standard.
Option C: Option C is incorrect: a JVP of 8 cm H₂O is not below optimal filling pressure in a patient with HFrEF; the target is euvolemia (JVP approximately 6–8 cm H₂O), and this patient may be close to that target; but the creatinine rise in the context of warm extremities and adequate urine output does not indicate that filling pressure has been reduced excessively.
Option D: Option D is incorrect: AHA/ACC/HFSA guidelines do not establish a 20% creatinine rise threshold mandating dose reduction; no such nephroprotective protocol from CARRESS-HF exists in this form — CARRESS-HF compared ultrafiltration versus pharmacological decongestion but did not establish a creatinine rise percentage threshold for guideline-mandated furosemide reduction.
Option E: Option E is incorrect: AHA/ACC/HFSA guidelines do not mandate transition from IV to oral furosemide at a specific JVP threshold of 10 cm H₂O; the transition to oral therapy is guided by clinical euvolemia (achievement of dry weight, absence of congestion signs), not a fixed JVP cutoff — and a JVP of 8 cm H₂O does not automatically indicate euvolemia in all patients.
13. A 58-year-old man is reviewed in clinic 14 days after an inferior STEMI (ST-elevation myocardial infarction) treated with primary PCI. His predischarge echocardiogram showed LVEF of 35% with inferior wall hypokinesis. He reports mild dyspnea when climbing stairs. Current medications: aspirin, clopidogrel, atorvastatin, metoprolol succinate 25 mg daily, and lisinopril 5 mg daily. Potassium is 4.6 mEq/L, creatinine 1.2 mg/dL (eGFR 62 mL/min/1.73m²). The cardiologist initiates eplerenone. At what dose should eplerenone be started, what is the titration plan, and what monitoring is required?
A) Eplerenone should be started at 50 mg daily (the EPHESUS target dose) to maximize MR blockade immediately; the 25 mg starting dose used in EPHESUS was only applicable to the acute in-hospital phase and is not appropriate for clinic initiation at 14 days; potassium should be checked once at 4 weeks
B) Eplerenone should be started at 25 mg every other day because this patient's eGFR of 62 mL/min/1.73m² places him in the moderate CKD category requiring reduced-frequency dosing; the standard every-other-day starting dose in CKD reduces peak eplerenone concentrations and lowers the hyperkalemia risk during the first month of therapy in post-MI patients on dual RAAS blockade
C) Eplerenone should be started at 25 mg daily; if potassium remains below 5.0 mEq/L and creatinine is stable at 1-week follow-up, the dose can be titrated to 50 mg daily — the EPHESUS target dose; monitoring should include potassium and creatinine at 1 week after initiation and after each dose change, then periodically thereafter; the combination of eplerenone with lisinopril requires close monitoring given their additive potassium-retaining effects
D) Eplerenone should be deferred until 30 days post-MI and initiated only if LVEF remains below 40% on a repeat echocardiogram at that time; the EPHESUS protocol required a confirmatory echocardiogram at 30 days before continuation of eplerenone, and the 14-day visit LVEF is considered a preliminary estimate that may overestimate LV dysfunction due to myocardial stunning
E) Eplerenone is not indicated at this visit because the 14-day post-MI timepoint falls outside the EPHESUS enrollment window of 3–7 days post-MI; after day 7, the pathophysiological rationale for MRA therapy (aldosterone-driven acute infarct expansion) is no longer operative, and eplerenone should be initiated only if the patient develops worsening HF symptoms at 30 days, qualifying him for the EMPHASIS-HF indication instead
ANSWER: C
Rationale:
This patient satisfies EPHESUS eligibility criteria (acute MI within 3–14 days, LVEF 40% or less, symptomatic HF, on background ACE inhibitor and beta-blocker, acceptable potassium and renal function), and the EPHESUS protocol directly informs the initiation and titration strategy. The EPHESUS protocol initiated eplerenone at 25 mg daily — not the target dose of 50 mg — recognizing that post-MI patients on dual RAAS blockade (ACE inhibitor and MRA) are at heightened hyperkalemia risk in the early post-infarction period when renal function may be in flux. After confirming that potassium remains below 5.0 mEq/L and creatinine is stable at the 1-week follow-up, the dose is increased to the target of 50 mg daily. This 25 mg → 50 mg titration with 1-week monitoring between each step is standard practice. Close monitoring of potassium and creatinine is particularly important in this patient because lisinopril (ACE inhibitor) reduces angiotensin II-mediated aldosterone secretion while eplerenone blocks the MR — both mechanisms reduce collecting duct potassium excretion additively.
Option A: Option A is incorrect: initiating eplerenone at 50 mg daily without a low starting dose is not the EPHESUS protocol or current clinical practice; the 25 mg starting dose was used throughout EPHESUS including in outpatient post-MI management, not only during the acute hospital phase.
Option B: Option B is incorrect: eGFR of 62 mL/min/1.73m² is not in the moderate CKD (stage 3) category requiring every-other-day dosing; eGFR 62 mL/min/1.73m² represents mild CKD (stage 2) and does not require alternate-day dosing; every-other-day eplerenone is not a recognized standard dosing strategy in any guideline.
Option D: Option D is incorrect: EPHESUS did not require a confirmatory echocardiogram at 30 days before continuation; enrollment was based on the index post-MI echocardiogram showing LVEF of 40% or less, and continuation did not require LVEF confirmation at 30 days.
Option E: Option E is incorrect: the EPHESUS enrollment window was 3–14 days post-MI (not 3–7 days); this patient at day 14 is at the outer boundary of the window but still eligible; and the pharmacological rationale for eplerenone (anti-fibrotic MR blockade, aldosterone-driven adverse remodeling post-MI) is operative throughout the window and beyond, not only in the first 7 days.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.